VERRICA PHARMACEUTICALS INC (VRCA) Stock Overview
USA - NASDAQ:VRCA - US92511W2070 - Common Stock
VRCA Key Statistics, Chart & Performance
The current stock price of VRCA is 4.15 USD. In the past month the price decreased by -5.47%. In the past year, price decreased by -74.06%.
VRCA Latest News, Press Relases and Analysis
VRCA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 49.71 | 759.85B | ||
| JNJ | JOHNSON & JOHNSON | 18.61 | 465.34B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 19.07 | 262.58B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.85 | 254.43B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 13.98 | 241.59B | ||
| MRK | MERCK & CO. INC. | 11.01 | 211.79B | ||
| PFE | PFIZER INC | 7.23 | 139.35B | ||
| SNY | SANOFI-ADR | 11.43 | 123.36B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.48 | 88.81B | ||
| GSK | GSK PLC-SPON ADR | 9.74 | 88.32B | ||
| ZTS | ZOETIS INC | 23.16 | 63.84B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 48.41 | 44.34B |
Related stock screener links
About VRCA
Company Profile
Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. The company is headquartered in West Chester, Pennsylvania and currently employs 71 full-time employees. The company went IPO on 2018-06-15. The firm's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. The company is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).
Company Info
VERRICA PHARMACEUTICALS INC
44 West Gay Street, Suite 400
West Chester PENNSYLVANIA 19380 US
CEO: Ted White
Employees: 71
Phone: 14844533300
VERRICA PHARMACEUTICALS INC / VRCA FAQ
What is the stock price of VERRICA PHARMACEUTICALS INC today?
The current stock price of VRCA is 4.15 USD. The price decreased by -1.89% in the last trading session.
What is the ticker symbol for VERRICA PHARMACEUTICALS INC stock?
The exchange symbol of VERRICA PHARMACEUTICALS INC is VRCA and it is listed on the Nasdaq exchange.
On which exchange is VRCA stock listed?
VRCA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for VERRICA PHARMACEUTICALS INC stock?
11 analysts have analysed VRCA and the average price target is 15.3 USD. This implies a price increase of 268.67% is expected in the next year compared to the current price of 4.15. Check the VERRICA PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VERRICA PHARMACEUTICALS INC worth?
VERRICA PHARMACEUTICALS INC (VRCA) has a market capitalization of 39.22M USD. This makes VRCA a Nano Cap stock.
How many employees does VERRICA PHARMACEUTICALS INC have?
VERRICA PHARMACEUTICALS INC (VRCA) currently has 71 employees.
What are the support and resistance levels for VERRICA PHARMACEUTICALS INC (VRCA) stock?
VERRICA PHARMACEUTICALS INC (VRCA) has a support level at 4.13 and a resistance level at 4.19. Check the full technical report for a detailed analysis of VRCA support and resistance levels.
Is VERRICA PHARMACEUTICALS INC (VRCA) expected to grow?
The Revenue of VERRICA PHARMACEUTICALS INC (VRCA) is expected to grow by 288.59% in the next year. Check the estimates tab for more information on the VRCA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy VERRICA PHARMACEUTICALS INC (VRCA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VRCA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VRCA, evaluating the profitability, health, valuation and growth aspects
- VERRICA PHARMACEUTICALS INC (VRCA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VERRICA PHARMACEUTICALS INC (VRCA) Sales and EPS estimates to see what analysts future expectations are.
- VERRICA PHARMACEUTICALS INC (VRCA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VERRICA PHARMACEUTICALS INC (VRCA) Insider and Institutional Ownership to learn about the owners and their transactions.
- VERRICA PHARMACEUTICALS INC (VRCA) Stock Chart to make your own analysis
- VERRICA PHARMACEUTICALS INC (VRCA) Latest news and press-releases to stay up to date.
Does VERRICA PHARMACEUTICALS INC (VRCA) stock pay dividends?
VRCA does not pay a dividend.
When does VERRICA PHARMACEUTICALS INC (VRCA) report earnings?
VERRICA PHARMACEUTICALS INC (VRCA) will report earnings on 2025-11-10.
What is the Price/Earnings (PE) ratio of VERRICA PHARMACEUTICALS INC (VRCA)?
VERRICA PHARMACEUTICALS INC (VRCA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-8.28).
What is the Short Interest ratio of VERRICA PHARMACEUTICALS INC (VRCA) stock?
The outstanding short interest for VERRICA PHARMACEUTICALS INC (VRCA) is 4.87% of its float. Check the ownership tab for more information on the VRCA short interest.
VRCA Technical Analysis
VRCA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VRCA. Both the profitability and financial health of VRCA have multiple concerns.
VRCA Financial Highlights
Over the last trailing twelve months VRCA reported a non-GAAP Earnings per Share(EPS) of -8.28. The EPS decreased by -58.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -124.27% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
VRCA Forecast & Estimates
11 analysts have analysed VRCA and the average price target is 15.3 USD. This implies a price increase of 268.67% is expected in the next year compared to the current price of 4.15.
For the next year, analysts expect an EPS growth of 88.63% and a revenue growth 288.59% for VRCA